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Abstract
Context: In older adults, loss of mobility due to sarcopenia is exacerbated in
men with low serum T. T replacement therapy is known to increase muscle
mass and strength, but the effect of weekly (WK) vs monthly (MO)
administration on specific fiber types is unknown.
Objective: To determine the efficacy of WK vs MO T replacement on the size
and functional capacity of individual fast and slow skeletal muscle fiber types.
Design, Setting, and Patients:
Subjects were randomized into a 5-month, double-blind, placebo-controlled
trial. All subjects (ages, 61–71 y) were community-dwelling men who had T
levels < 500 ng/dL.
Intervention: Subjects were dosed weekly for 5 months, receiving
continuous T (WK, n = 5; 100 mg T enanthate, im injection), monthly cycled
T (MO, n = 7; alternating months of T and placebo), or placebo (n = 7).
Muscle biopsies of the vastus lateralis were obtained before and after
treatment.
Main Outcome Measures: Main outcomes for individual slow and fast fibers
included fiber diameter, peak force (P 0), rate of tension development,
maximal shortening velocity, peak power, and Ca2+ sensitivity.
Results: Both treatments increased fiber diameter and peak power, with WK
treatment 5-fold more effective than MO in increasing type I fiber P0. WK
effects on fiber diameter and force were 1.5-fold higher in slow fibers
compared to fast fibers. In fast type II fibers, diameter and P 0 increased
similarly between treatments. The increased power was entirely due to
increased fiber size and force.
Conclusions: In conclusion, T replacement effects were fiber-type
dependent, restricted to increases in cell size, P 0, and peak power, and
dependent on the paradigm selected (WK vs MO).
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The loss of muscle mass and strength with age can greatly limit
the ability of older adults to maintain normal daily activities and
physical function.1,–4 This problem is exacerbated in hypogonadal men
with low T.5 T replacement therapy has been shown to protect against
losses in muscle mass and strength by increasing muscle protein
synthesis and decreasing protein degradation.5,6 The gains observed
with T treatment are both age- and dose-dependent, with greater
effects typically seen in younger compared to older men.5,7 Ferrando et
al6 found that chronic T administration increased lean body mass and
strength in older men and, in the fasted state, stimulated reutilization
of intracellular amino acids produced during protein breakdown. The
observed decrease in protein breakdown in the T-treated group is
important because an age-associated increase in skeletal muscle
proteolysis is thought to contribute to the sarcopenia experienced by
older adults.8
T administration, depending upon the dose and administration
frequency, can be associated with adverse side effects including an
increased hemoglobin and hematocrit and decreased high-density
lipoprotein cholesterol.9 Bhasin et al9 studied the dose dependency of T
therapy on gains in muscle strength and the severity of adverse effects
and found both to increase with the dose. They concluded that the
best trade-off was achieved with an intermediate T dose of 125 mg
weekly injections.9 Besides dose, the type of T administered and the
duration of T administration may have implications on the functional
responses in younger and older adults. The hormone-induced increase
in the anabolic response may decrease with the duration of
administration due to a return of the androgen receptor expression to
pretreatment values.10 To address both the adverse effects and
diminishing anabolic response of prolonged T administration, SheffieldMoore et al11 studied a monthly cycled T regimen that used half the
dose of the standard continuous therapy. They alternated months of T
and placebo (PL) treatment for a 5-month period and compared the
results with a group receiving standard continuous therapy. Despite
declining serum T levels in the cycled months of PL injection, muscle
strength, muscle protein synthesis, and lean body mass increased, and
the percentage of body fat was reduced after 5 months of treatment in
both groups. The rate of increase in lean body mass and extensor leg
strength was less in the group receiving T in a cycled fashion, but both
groups reached similar levels by 5 months.
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To date, little is known about the specific effects of T
replacement (either WK or MO) on the individual fast and slow fiber
types of limb skeletal muscle. Sinha-Hikim et al12 found significant
increases in vastus lateralis volume and slow type I and fast type II
fiber area, but only at serum T levels > 1000 ng/dL, which represent
levels on the upper end of normal (or slightly above) and are much
higher than seen in this study. Increases in leg and arm muscle
strength suggest an improved fiber function, but the extent to which
the adaptations are specific to a given fiber type are unknown.
Additionally, the relative importance of changes in force and velocity in
increasing peak power and whether or not there are changes in
myofilament Ca2+ sensitivity that contribute to functional improvement
are also unexplored. Thus, the goal of this study was to answer these
questions using muscle biopsies obtained from the subject population
previously reported on by Sheffield-Moore et al.11

Subjects and Methods
Ethical approval
This study was approved by the University of Texas Medical
Branch (UTMB) and Marquette University Institutional Review Boards
and complied with the Declaration of Helsinki. Written informed
consent was obtained from all subjects.

Subjects
The subjects were a subset of a larger study of 24 individuals
recruited by Sheffield-Moore et al.11 From that subject population, we
received muscle biopsies from 19 healthy, community-dwelling older
men (ages, 60–85 y). In the case of the subjects not studied, there
was insufficient sample size. All subjects had endogenous levels of
serum total T in the lower half of the normal range (between 204 and
485 ng/dL). The recruitment process, preselection battery of tests, and
exclusion criteria were exactly as described by Sheffield-Moore et al.11

Study design
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The study design was as described previously and reviewed
here. We conducted a randomized, double-blinded, PL-controlled trial
in older men to test whether T administered either continuously or
cyclically improves contractile function of single slow and fast fibers
isolated from the vastus lateralis muscle of older men. All men were
randomized by the UTMB Investigational Drug Service pharmacist into
the following groups: 1) weekly T (WK; n = 8; 100 mg T-enanthate im
per week); 2) monthly T (MO; n = 8; alternating months of 100 mg Tenanthate and PL per week); or 3) PL (n = 8). Serum T levels were
measured at the nadir before the next injection using the Bayer Advia
Centaur immunoassay (Bayer Corp) as described in the Supplemental
Data. The subset of subjects (ages, 61–71 y) for these data totaled 5,
7, and 7 for the WK, MO, and PL groups, respectively. Subjects were
dosed weekly for 5 months by a research nurse at the UTMB Institute
for Translational Science Clinical Research Center.11
11

Cell studies
Muscle biopsies
Before and at the end of the 5 months of T therapy, muscle
biopsies (∼100–200 mg) were taken from the vastus lateralis
approximately 15–20 cm above the knee.11 The portion used for the
present experiment was immediately placed in cold skinning solution
(composition in mm: 125 K propionate, 20 imidazole [pH 7.0], 2
EGTA, 4 ATP, and 1 MgCl2, and 50% glycerol vol/vol), and shipped
overnight at 4°C to Marquette University, where it was stored at
−20°C. All of the fiber studies were conducted within 4 weeks of the
biopsy.

Solutions and single-fiber isolation procedures
The relaxing (pCa 9.0, where pCa is the negative log of the Ca2+
concentration) and activating (pCa 4.5) solutions and fiber isolation
procedure were as previously described.13,–15 The total and free
concentrations of each metal, ligand, and metal ligand complex in the
solutions were calculated using an iterative computer program with
stability constants adjusted for temperature, pH, and ionic
strength.16,17
Journal of Clinical Endocrinology and Metabolism, Vol 100, No. 2 (February 2015): pg. E223-E231. DOI. This article is ©
2015 Oxford University Press and permission has been granted for this version to appear in e-Publications@Marquette.
Oxford University Press does not grant permission for this article to be further copied/distributed or hosted elsewhere
without the express permission from Oxford University Press.

5

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

On the day of an experiment, a single fiber segment was
isolated from the muscle bundle, submerged in relaxing solution, and
mounted between a force transducer and a position motor as
previously described.13,14 The fiber was viewed at ×800, sarcomere
length was adjusted to 2.5 μm, and fiber length (FL) and diameter
were determined.15 Fiber cross-sectional area (CSA) was calculated
from the diameter.18

Determination of peak force (P0), rate of tension
development (ktr), maximal unloaded shortening
velocity (V0), and force-velocity relationship
Fibers were maximally activated in pCa 4.5 solution (15°C), and
peak force (P0) was recorded. Fiber V0 (FL s−1) was measured by the
slack test.14
In slow fibers, we determined the rate constant for force
redevelopment (ktr) by generating a rapid slack (20% of FL) and reextension of a fully activated fiber.19,20 The redevelopment of tension
was fit by a single exponential, and ktr was determined.
The force-velocity relationship was determined from a series of
isotonic releases as described previously.13 Vmax was defined as the
intercept of the force-velocity curve with the velocity axis, and peak
absolute power was calculated from P0, Vmax, and a/P0 where the latter
parameter specifies the curvature of the force-velocity relation.13 For
graphical purposes, composite force-velocity-power relationships were
plotted using the mean parameters.13

Determination of the pCa-force relationship and fiber stiffness
A separate group of fibers was used to determine the pCa-force
relationship, which reflects the myofibril Ca2+ sensitivity. These
experiments were conducted exactly as described by Widrick et al.13
Hill plots were used to determine the minimal Ca2+ required for force
development (activation threshold) and that required for 50%
activation (pCa50).13 To determine fiber stiffness, fibers were vibrated
first in relaxing solution (pCa 9) and then at the peak of the pCa 4.5
activation with a sinusoidal length change of 0.05% of FL and 1.5
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kHz.15 Changes in length (Δlength) and force (Δforce) were used to
calculate peak elastic modulus (E0) as follows: {E0 = [Δforce in
activating solution − Δforce in relaxing solution/(Δlength)] (FL/CSA)}.

Fiber type identification
After the contractile measurements, fibers were solubilized in 10 μL of
1% SDS sample buffer and stored at −80°C. Fibers were identified as
fast type II or slow type I based on their myosin heavy chain isoform
determined from 5% PAGE.14,21

Statistical analysis
Pre- and post-treatment means were analyzed using a two-tailed t
test. Statistical significance was accepted at P < .05.

Results
Cell diameter and P0
The effects of WK and MO T therapy on fiber diameter, P0, and
V0 for slow type I and fast type II fibers are shown in Table 1. Before
treatment, the MO group had significantly smaller fiber diameters for
both slow type I and fast type II fiber than the PL group. The WK and
MO treatments had differential effects, with WK significantly increasing
type I fiber diameter and MO significantly increasing type II fiber
diameter (Table 1). Although not significant, there was a trend (P
< .1) for MO to increase type I fiber diameter. The PL group showed a
decreased type II fiber diameter, which resulted in an increased
specific force (Table 1).
Table 1. Type I and II Fiber Diameter, P0, and V0 With Weekly and Monthly T
Diameter, μm P0, mN

P0, kN/m2

V0, FL/s

Pre
Post
% Difference

101 ± 2 (54)
99 ± 2 (75)
−3

0.89 ± 0.04 (53)
0.88 ± 0.04 (71)
−1

111 ± 3 (53)
112 ± 3 (71)
1

0.71 ± 0.04 (53)
0.66 ± 0.02 (73)
−7

Pre
Post

102 ± 2 (60)
118 ± 4 (48)a

0.87 ± 0.03 (58)
1.25 ± 0.08 (48)a

106 ± 2 (58)
111 ± 2 (48)

0.66 ± 0.03 (58)
0.64 ± 0.02 (48)

VL Muscle
Type I
PL

Weekly
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% Difference

Diameter, μm P0, mN
16
44

P0, kN/m2
4

V0, FL/s
−3

Pre
Post
% Difference

90 ± 2 (70)b
94 ± 2 (66)c
5

0.76 ± 0.02 (70)b
0.82 ± 0.03 (65)a
8

118 ± 2 (70)
116 ± 2 (65)
−2

0.66 ± 0.02 (70)
0.68 ± 0.02 (65)
3

Pre
Post
% Difference

96 ± 2 (71)
86 ± 2 (60)a
−10

0.89 ± 0.04 (67)
0.83 ± 0.03 (60)
−7

128 ± 4 (67) 2.96 ± 0.14 (66)
143 ± 4 (60)a 2.72 ± 0.21 (59)
11
−8

Pre
Post
% Difference

96 ± 3 (22)
106 ± 4 (44)
10

0.98 ± 0.07 (21)
1.26 ± 0.09 (44)a
29

130 ± 5 (21) 2.79 ± 0.25 (21)
141 ± 3 (44)a 2.47 ± 0.11 (44)
9
−11

Pre
Post
% Difference

85 ± 2 (49)b
93 ± 2 (39)a
9

0.81 ± 0.03 (46)
0.99 ± 0.03 (37)a
22

144 ± 3 (46)b 2.44 ± 0.08 (46)b
144 ± 3 (37) 2.51 ± 0.14 (37)
0
3

VL Muscle
Monthly

Type II
PL

Weekly

Monthly

Abbreviation: VL, vastus lateralis muscle. Values represent means ± SE with the
number of fibers studied in parentheses. The weekly group received T weekly for 5
months; the monthly group received T weekly during months 1, 3, and 5.
aSignificant difference (P < .05) between pre and post mean for a given group.
bSignificant difference (P < .05) between PL pre mean and treatment group pre mean.
cSignificant difference (P < .10) between pre and post mean for a given group.

For the type I fiber, both treatments increased the absolute P0
(millinewtons [mN]), but the magnitude of the effect was considerably
greater with WK (44% increase) vs MO (8% increase) (Table 1). The
increased type I fiber force appears primarily to be due to the increase
in fiber size because the specific force (kilonewtons [kN]/m2) was not
altered by either treatment. Similar results were observed for the type
II fiber, except the percentage increase in absolute P0 was of the same
magnitude with both treatments, and specific force significantly
increased with WK (Table 1).

V0, ktr, and peak power
For both fiber types, the V0 was unaltered by WK or MO (Table
1), and the type I fiber ktr was also unaffected by the treatments, with
mean values ranging from 1.25 ± 0.03 to 1.29 ± 0.03−s for the three
groups. Although there was no change in V0, type I fiber peak power
significantly increased in the WK and MO groups (Figure 1 and
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Supplemental Table 1), and like force, the increase was greater with
WK (41 vs 13%). For the type II fiber, there was a trend (P < .1) for
both treatments to increase peak power (Figure 1 and Supplemental
Table 1). The curvature of the force-velocity relationship was unaltered
by the treatments, except for type II fibers where WK significantly (P
< .05) reduced the curvature as reflected by an increased a/P0 ratio
(0.072 ± 0.004 vs 0.081 ± 0.004). There were no changes in relative
peak power (Supplemental Table 1), suggesting that the increase in
absolute peak power is primarily due to a T-induced increase in fiber
size. Figure 1 shows that power increased with both treatment
paradigms across the entire force-power spectrum from very light to
heavy loads, and across this range the increase was greater with WK
compared to MO.

Figure 1. Force-power relationships for PL and treatment groups. Continuous lines
represent the pretreatment and dashed lines represent the post-treatment forcepower relationships for type I and type II fibers for PL and weekly and monthly
treatment groups.
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E0 and the P0/E0 ratio
The E0, a reflection of the number of attached cross-bridges per
CSA, was not significantly altered by either paradigm in type I (Figure
2A) or type II fibers. For both groups combined, the mean stiffness
(E0) was 2.19 ± 0.04 (n = 160) and 1.83 ± 0.04 (n = 44) for type I
and II fibers, respectively. The lack of change in E0 with treatment
suggests that neither WK nor MO affected the number of cross-bridges
per CSA. The P0/E0 ratio, an indicator of the force per cross-bridge,
was also unaltered except for the type I fibers where WK significantly
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increased the ratio (Figure 2B).

Figure 2. Stiffness and force stiffness ratio. A, Mean type I fiber stiffness before (E0WK-Pre) and after (E0-WK-Post) weekly T treatment, and before (E0-MO-Pre) and after
(E0-MO-Post) monthly T treatment. B, Mean force/stiffness ratio before (P0/E0-WK-Pre)
and after (P0/E0-WK-Post) weekly T treatment, and before (P0/E0-MO-Pre) and after
(P0/E0-MO-Post) monthly T treatment. *, Significant difference (P < .05) between pre
and post mean for a given group.
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Calcium sensitivity
The WK and MO treatments had no effect on calcium sensitivity
of the contractile filaments, as reflected by no change in the Ca2+
required to initiate contraction (activation threshold) or that needed
for one-half maximal activation (pCa50). Additionally, the slope of the
force-pCa relationship (Hill plot) below (N2) and above (N1) one-half
maximal activation was unaltered (Supplemental Table 2).

Comparison of T administration to fiber size and force
outcomes
From Table 1, it is clear that the primary effect of T therapy
administered either continuously or in a cycled fashion was to increase
fiber size and absolute force. To further assess this aspect, we graphed
the relationship between fiber diameter and peak absolute force for
each individual for type I (Figures 3 and 4) and type II (Supplemental
Figures 1 and 2) fibers. As is often seen in the clinical realm, some
men respond to a given dose and others do not, thus requiring dose
adjustment to manage symptoms. As such, in this study, where dose
adjustment was not performed as done clinically, certain men
responded to their administration paradigm (WK or MO), and others
did not. If subjects showed a significant increase in fiber force in both
slow and fast fibers, they were classified as responders (Tables 2 and
3, Figures 3 and 4 and Supplemental Figures 1 and 2). With WK
therapy, subjects WK 1 and WK 2 both showed an increase in type I
and type II fiber diameter and force (post-treatment fibers all shifted
to the right and up on the plot; Figure 3 and Supplemental Figure 1).
WK 3 was a responder who showed an increased force with no change
in fiber diameter (Figure 3). With MO treatment, subjects MO 1 and
MO 2 (Figure 4 and Supplemental Figure 2) responded similarly to
subjects WK 1 and WK 2. Also, with MO therapy we observed two
subjects (MO 3 and MO 4) who were partial responders showing
significant increases in fast type II fiber P0 but no change in the slow
type I fiber type.
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Figure 3. Relationship between type I fiber diameter and peak Ca2+-activated force
(P0) for weekly T (WK) treatment. Each symbol represents the results of a single
vastus lateralis type I fiber for each subject where open squares are pretreatment
fibers and filled squares are post-treatment fibers. The gray shaded triangle and gray
shaded circle are the mean pre- and post-treatment values for the PL group,
respectively.

Figure 4. Relationship between type I fiber diameter and peak Ca2+-activated force
(P0) for monthly T (MO) treatment. Each symbol represents the results of a single
vastus lateralis type I fiber for each subject where open squares are pretreatment
fibers and filled squares are post-treatment fibers. The gray shaded triangle and gray
shaded circle are the mean pre- and post-treatment values for the PL group,
respectively. The asterisk indicates that subject MO 3, although a nonresponder for
the slow type I fiber, was a responder for the fast type II fiber.
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Table 2. Age, Leg Strength, and Plasma T for PL, MO, and WK Groups
Groups

Age,
y

PL

65 ±
3

Monthly
(MO)

72 ±
8

Leg Extension
Strength, kg

Leg Curl
Strength, kg

T, ng/dL

Pre

Post

Pre

Post

Pre

Post

70 ± 21

74 ± 13

46 ± 6

48 ± 7

344 ±
85

343 ± 73

73 ± 15

85 ± 19

44 ± 7

50 ± 11a

357 ±
103

665 ±
25a,+

Weekly
73 ± 66 ± 16
83 ± 17a
40 ± 9 51 ± 12a 341 ±
659 ±
(WK)
8
85
282a,+
Values are expressed as means ± SD. WK group received 100 mg T-enanthate weekly
throughout the 5-month study; MO group received 100 mg T-enanthate weekly in
alternating months.
aPost value significantly different from pre value, P ≤ .05.
+Post value significantly different from PL post value, P < .05.

Table 3. Leg Strength, Type I Fiber P0, and Plasma T of Individual Subjects
Individuals

Leg Extension
Strength, kg

Type I Fiber P0, T, ng/dL
mN

Pre

Post

Pre

Post

Pre Ave 1–5 Highest
Mo

WK 1
(Responder)

79.4

86.2

1.01

2.12a

261 503

553

WK 2
(Responder)

41.2

60.8

0.65

1.22a

204 613

818

WK 3
(Responder)

72.6

81.6

0.76

0.93a

356 595

782

WK 4 (NonRes) 77.1

86.2

0.92

0.98

401 894

952

WK 5 (NonRes) 74.8

97.5

0.86

0.71

280 386

492

277 365

584

MO 1
(Responder)

77.1

81.6

0.71

0.94a

MO 2
(Responder)

74.8

72.6

0.69

0.96a

485 473

669

MO 3 (PartRes) 54.4

61.2

0.98

0.86

260 674

985

MO 4 (PartRes) 77.1

-

0.68

0.63

275 460

682

MO 5 (NonRes) 104.3

113.4

0.81

0.77

409 459

598

MO 6 (NonRes) 61.2

93.0

0.83

0.83

456 500

642

MO 7 (NonRes) 68.0

68.0

0.62

0.64

241 384

617

PL 1

90.7

74.8

1.03

1.05

379 382

463

PL 2

56.7

63.5

-

0.77

255 253

318

PL 3

113.4

95.2

0.92

1.24a

428 388

527

PL 4

59.0

59.0

1.01

0.73a

444 387

444

PL 5

68.0

81.6

1.08

0.63a

417 423

470

PL 6

63.5

68.0

0.72

0.65

270 275

331

PL 7

59.0

81.6

0.56

0.48

226 206

226

Journal of Clinical Endocrinology and Metabolism, Vol 100, No. 2 (February 2015): pg. E223-E231. DOI. This article is ©
2015 Oxford University Press and permission has been granted for this version to appear in e-Publications@Marquette.
Oxford University Press does not grant permission for this article to be further copied/distributed or hosted elsewhere
without the express permission from Oxford University Press.

14

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Abbreviations: NonRes, non-responder; PartRes, partial responder to T treatments;
WK, received 100 mg T-enanthate weekly throughout the 5-month study; MO,
received 100 mg T-enanthate weekly in alternating months; Ave 1–5 Mo, the mean T
over the study calculated from each months' T.
aPost value significantly different from pre value, P ≤ .05.

Table 2 shows the average leg strength (extension and flexion)
as well as serum T levels before and after T therapy for all 24 subjects.
Before treatment, all subjects participating in this study (7 PL, 5 WK,
and 7 MO) had circulating total T concentrations in the lower half of
the normal range (333 ± 21 ng/dL), and the mean values stayed low
in the PL group (284 ± 24 ng/dL) and cycled up and down in the MO
group with a 5-month value of 474 ± 38 ng/dL, whereas in the WK
group, T increased in the first month and remained high with 598 ± 84
ng/dL at 5 months. Individual changes in T for the WK, MO, and PL
subjects are shown in Table 2. The subjects with the greatest cellular
response in the WK group started with low serum T that increased with
treatment to above 500 ng/dL for both the average and peak values
(subjects WK 1 and WK 2; Table 2). Non-responders either failed to
show an increase in serum T above 500 ng/dL (subject WK 5) or had
relatively high pretreatment T levels (subject WK 4).

Discussion
The use of T to treat adult males with serum T levels in the
lower half of the normal range has been shown to improve muscle
strength, but the ideal treatment paradigm and the selective effects on
fast and slow fiber types are unknown.10,–12 A novel finding of this
study is that P0 and peak power of the slow type I and fast type II
fibers significantly increase in response to both continuous weekly
administration of T for 5 months (WK) and monthly administration
(MO) where T is administered weekly in months 1, 3, and 5 with PL
injections in months 2 and 4.
Fiber type differences with T therapy were observed with the
WK paradigm to be 5-fold more effective than MO in increasing the
slow type I fiber P0, whereas with the fast type II fiber P0 increases
were similar between treatments. The higher sensitivity of the type I
fiber to T therapy agrees with the observation of Sinha-Hikim et al,12
who reported type I fiber area to increase in response to T
supplements at levels less than that required for type II fibers.
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Interestingly, subjects that responded well to WK treatment showed
significant increases in fiber diameter and P0 in slow and fast fibers,
whereas with the MO paradigm, in addition to responders with
adaptations in both fiber types, we observed partial responders with
significant functional changes in fast but not slow fibers. This likely
resulted from the lower response of slow fibers to MO treatment (Table
1). Our results demonstrate that slow fibers respond better to a
continuous cellular exposure to T, whereas with fast fibers a threshold
level of T is required, but not a continuous exposure. The increased
effectiveness of WK over MO treatment for the type I fiber might not
have been due to the pattern of administration, but rather to the
different cumulative T dosage over the 5 months. An explanation for
this fiber type difference is not readily apparent, but it might result
from differences in receptor sensitivity and/or half-life of the cellular
responses to T.10 To our knowledge, fiber type differences in T receptor
sensitivity or response to hormone have not been studied.
Our data suggest that the cellular improvements in P0 and peak
power with T replacement were largely dependent upon the increase in
fiber size. Thus, for the most part (an exception being the effect of WK
on fast fibers, and for subject WK 3 both fiber types), there was no
increase in relative force (kN/m2). As expected, the PL group, with the
exception of a reduced type II fiber diameter and specific force,
showed no change in slow or fast fiber function. The fast fiber-specific
force increased due to the fiber atrophy. Although the cause of the
fiber atrophy in the PL group is unknown, it could be a result of
changes with aging over the 5-month period.22 Fiber stiffness (E0), an
indicator of the number of cross-bridges, did not change with either
WK or MO treatment. However, the P0/E0 ratio did significantly
increase with WK in the slow type I fiber, which suggests an increase
in the force per cross-bridge in this fiber. This adaptation should result
in an increased relative force that increased, but not significantly.
Thus, we conclude that any increase in force per cross-bridge with T
treatment was relatively unimportant compared to the force increase
due to the larger fiber size.
Importantly, there were no changes in any kinetic parameter
because neither V0 nor the ktr was altered by T replacement. The Ca2+
sensitivity of activation, as reflected by the activation threshold, pCa50,
and slope of the Ca2+-force relationship (Supplemental Table 2), was
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unaltered as well. Additionally, there was no change in the curvature
of the force-velocity relationship (a/P0 ratio) that could have increased
peak power. These results suggest that the T therapy did not alter the
kinetics of the cross-bridge cycle and that the observed increases in
power (Figure 1) can be entirely attributed to the increased force.
An explanation for individual differences in response to T
replacement therapy is not known and may involve factors not studied
here. One possibility is that the initial serum T level and the extent of
its increase with therapy are important to whether or not therapy
produces significant cell responses. Although our data support this
hypothesis (Table 2), future studies powered to address this question
are needed. The variability in subject response to T therapy could also
result from monthly variations in serum T levels achieved in response
to the 100-mg monthly dose. This seems unlikely because for all of the
WK subjects there was very little variation around their 1- to 5-month
average.11 Because there were no data on T therapy effects on single
fibers, the study was powered based on the known treatment effects
on leg extension strength. Significant increases with treatment in
some of the subjects (responders) suggest that the study was
adequately powered. Nonetheless, the possibility exists that we may
have observed more responders if the number of observations per
subject was increased.
Although it is not clinically practical to base a T therapeutic
regimen on the fiber type distribution of the individual, we believe
these data suggest that similar whole-muscle functional benefits occur
in response to cycled and standard continuous T administration by
virtue of the similarity in the cellular-level responses observed in type
II fibers. Older men generally have significant muscle atrophy with
selective loss of the fast type II fiber,22 which is considerably more
powerful than type I fibers. To prevent large losses in peak power with
aging, it is important to reduce atrophy and loss of function in the type
II fiber. In that regard, the MO paradigm is equally as effective as the
WK paradigm with one-half the dose of T.
In conclusion, our work demonstrates for the first time that the
improvements in skeletal muscle function in older men after T
replacement therapy are fiber-type dependent and restricted to
increases in cell size, P0, and peak power, and that the degree of
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change in each fiber type depends on the treatment paradigm selected
weekly vs monthly. Specifically, we found that monthly T
administration increased type II fiber function equally to weekly
administration. Because type II fibers show the greatest atrophy and
are most often lost with aging, the monthly paradigm of T
administration affords equal gains in fiber power with half the dose of
T as weekly administration. Overall, these results suggest that
improvements in single fiber function in skeletal muscle are possible
with both standard weekly T administration and a monthly paradigm.
Future studies are needed to determine the mechanisms involved,
such as the role of IGF-1, in mediating the functional changes in slow
and fast fiber function.
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Footnotes
Abbreviations:
CSA cross-sectional area
E0 peak elastic modulus
FL fiber length
kN kilonewton
ktr rate of tension development
mN millinewton
MO monthly
P0 peak force
pCa negative log of the Ca2+ concentration
PL placebo
V0 maximal unloaded shortening velocity
WK weekly.
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Supplemental Methods
Testosterone assay. Serum testosterone was determined using The ADVIA Centaur Testosterone
assay e x a c t l y a s d e s c r i b e d b y t h e m a n u f a c t u r e r ( ) . I t is a competitive immunoassay
using direct chemiluminescent t e ch nol o gy. Testosterone in the patient sample competes with
acridinium ester- labeled testosterone in the Lite Reagent for a limited amount of polyclonal rabbit
anti testosterone antibody bound to monoclonal mouse anti-rabbit antibody, which is coupled to
paramagnetic particles in the solid phase. The assay uses testosterone releasing agent to release
bound testosterone from the endogenous binding proteins in the sample. The system automatically
performs the following steps : Dispenses 15 µL of sample and 50 µL of releasing agent into a cuvette;
Washes the reagent probe with 100 µL of probe wash ; Dispenses 50 µL of Lite reagent and 300 µL
of solid phase and incubates for 5.0 minutes at 37°C; Separates, aspirates, and washes the cuvettes with
reagent water ; Dispenses 300 µL each of acid reagent and base reagent to initiate the chemiluminescent
reaction.

Supplemental Figure 1: Relationship between type II fiber diameter and peak Ca2+-activated force
(P 0 ) for weekly testosterone (WK) treatment
Each symbol represents the results of a single vastus lateralis type II fiber for each subject where open
squares are pre-treatment fibers and filled squares are post-treatment fibers. For subject WK 2 no type II
pre-treatment fibers were studied. The gray shaded triangle and gray shaded circle are the mean pre- and
post-treatment values for the placebo group, respectively.
Supplemental Figure 2: Relationship between type II fiber diameter and peak Ca2+-activated force
(P 0 ) for monthly testosterone (MO) treatment
Each symbol represents the results of a single vastus lateralis type II fiber for each subject where open
squares are pre-treatment fibers and filled squares are post-treatment fibers. The gray shaded triangle and
gray shaded circle are the mean pre- and post-treatment values for the placebo group, respectively.
Subject MO 1 is not shown as no post-treatment fast fibers were isolated from this sample.

Supplemental Table 1. Type I and II fiber peak power with weekly and monthly TE
Absolute Peak Power

Relative Peak Power

uN*FL*s-1

uN*FL*s-1

kN*m-2*FL*s-1

kN*m-2*FL*s-1

Type I

Type II

Type I

Type II

Pre

10.18 ± 0.53 (47)

46.18 ± 2.71 (48)

1.31 ± 0.03 (47)

6.99 ± 0.34 (48)

Post

10.72 ± 0.65 (53)

45.53 ± 3.10 (37)

1.39 ± 0.05 (53)

8.28 ± 0.63 (37)†

% difference

5

-1

6

18

1.25 ± 0.05 (49)

6.51 ± 0.37 (16)

65.99 ± 4.77 (41)

1.25 ± 0.03 (44)

7.60 ± 0.44 (41)

Muscle
VL
Placebo

Weekly
Pre

10.40 ± 0.46 (49)
**

51.23 ± 4.29 (16)
†

Post

14.62 ± 1.20 (44)

% difference

41

29

0

17

Pre

8.43 ± 0.26 (68)*

47.12 ± 3.24 (35)

1.33 ± 0.04 (68)

8.41± 0.50 (35)*

Post

9.53 ± 0.39 (58)**

54.22 ± 2.36 (27)†

1.36 ± 0.04 (58)

8.31 ± 0.52 (27)

Monthly

% difference
13
15
2
-1
Values represent means ± SE; VL = vastus lateralis muscle; FL = fiber length; Weekly group received testosterone (TE) weekly for five
months; Monthly group received TE weekly during months 1, 3 and 5.
**
Significant difference (p < 0.05) between pre and post means for a given group
*
Significant difference (p < 0.05) between placebo pre means and subject pre means
†
Significantly different (p < 0.10) between pre and post mean for a given group

Supplemental Table 2. Calcium sensitivity of slow type I and fast type II fibers
Condition

Activation Threshold

pCa50

N1

N2

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Type I

6.58 ± 0.02

6.57 ± 0.01

5.72 ± 0.01

5.70 ± 0.01

2.10 ± 0.09

2.14 ± 0.07

2.84 ± 0.06

2.80 ± 0.06

Type II

6.46 ± 0.06

6.53 ± 0.03

5.92 ± 0.04

5.86 ± 0.01

1.85 ± 0.20

2.13 ± 0.11

4.68 ± 0.72

3.89 ± 0.21

Type I

6.53 ± 0.01

6.59 ± 0.02

5.87 ± 0.05

5.79 ± 0.02

1.85 ± 0.07

2.00 ± 0.07

3.32 ± 0.07

3.04 ± 0.08

Type II

6.54 ± 0.10

6.55 ± 0.09

5.90 ± 0.01

5.92 ± 0.01

1.91 ± 0.11

1.92 ± 0.09

4.34 ± 0.55

5.36 ± 0.85

Weekly (WK)

Monthly (MO)

2+

All data are pCa units (-log of Ca concentration) expressed as means ± SE; WK type I fibers pre treatment n = 30, post n = 37; WK type II fibers
pre treatment n= 7, post n = 15; MO type I fibers pre treatment n = 50, post n = 43; MO type II fibers pre treatment n = 7, post n = 14; Activation
2+
2+
Threshold is Ca that just elicits force, pCa50 equals –log of Ca concentration that elicits 50% of peak tension; N1 and N2 are slope of Hill plot
for values greater than and less than half-maximal activation, respectively.

